Loading
Genetic Neurodegenerative Diseases / Genetics and Neurodevelopmental Disorders · Journal article
Epilepsy & Behavior · July 16, 2026
A consensus or society position rather than new primary data.
This narrative review synthesizes current understanding of STXBP1-related disorders, a rare monogenic developmental and epileptic encephalopathy affecting approximately 1 in 30,000–40,000 individuals, characterized by neurodevelopmental impairment, early-onset seizures, and variable long-term outcomes. Existing management is empirical; emerging precision approaches including gene replacement, antisense oligonucleotides, and epigenetic modulation are positioning STXBP1-RD as a model for mechanism-based therapeutic development in rare monogenic DEEs.
Narrative review. Studies of STXBP1-related disorders, including molecularly confirmed patient cohorts, mechanistic investigations, and clinical trial data..
STXBP1-RD affects approximately 1 in 30,000–40,000 individuals and is among the most common monogenic DEEs Over 300 pathogenic variants identified, predominantly de novo heterozygous, with haploinsufficiency as principal mechanism Seizure onset typically occurs within first months of life, with vast majority presenting in first year
Mortality and SUDEP described qualitatively ('modest in absolute terms', 'disproportionate contribution'); precise incidence rates not stated.
Clinicians should recognize STXBP1-RD as a leading cause of monogenic DEE with heterogeneous seizure trajectories and significant neurodevelopmental burden. Current empirical management relies on phenobarbital, clobazam, and ketogenic diet; emerging precision approaches warrant inclusion in treatment planning and clinical trial enrollment discussions as mechanism-based therapies mature.
A comprehensive narrative review synthesizing mechanistic understanding and therapeutic evidence across multiple modalities for a rare monogenic encephalopathy, intended to inform clinical practice and research strategy.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize STXBP1-RD as a leading cause of monogenic DEE with heterogeneous seizure trajectories and significant neurodevelopmental burden. Current empirical management relies on phenobarbital, clobazam, and ketogenic diet; emerging precision approaches warrant inclusion in treatment planning and clinical trial enrollment discussions as mechanism-based therapies mature.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
STXBP1- related disorders (STXBP1-RD), caused by pathogenic variants in STXBP1 encoding the presynaptic protein MUNC18-1, affects approximately 1 in 30,000-40,000 individuals and is among the most common monogenic developmental and epileptic encephalopathies (DEEs). It is characterized by universal neurodevelopmental impairment, early-onset epilepsy, movement disorders, and autism spectrum features, yet treatment remains largely empirical. We conducted a comprehensive narrative review of studies indexed in PubMed/MEDLINE, Embase, Cochrane Library, ClinicalTrials.gov, and American Epilepsy Society proceedings through January 2026, synthesizing molecularly confirmed cohorts, mechanistic studies, and therapeutic investigations. Over 300 pathogenic variants have been identified, predominantly de novo heterozygous, with haploinsufficiency as the principal mechanism. Seizure onset typically occurs within the first months of life, with the vast majority presenting in the first year. Two broad trajectories emerge across cohorts: spontaneous seizure remission in a substantial minority - most within the first year - and persistent drug-resistant epilepsy in the remainder, with a significant proportion experiencing frequent seizures at long-term follow-up. Severe to profound intellectual disability affects the great majority of individuals; independent ambulation and functional verbal communication are achieved by roughly half and less than one-third, respectively. Movement disorders and autism spectrum features are common, and mortality, while modest in absolute terms, includes a disproportionate contribution from SUDEP. Current management is empirical, with phenobarbital, clobazam, and ketogenic diet supported by the most consistent retrospective cohort evidence for seizure reduction. Emerging precision approaches include AAV-mediated gene replacement, antisense oligonucleotides, 4-phenylbutyrate, CRISPR-based transcriptional activation, microRNA inhibition, and serotonergic modulation. Advances in natural history studies and biomarker development are accelerating mechanism-based therapies, positioning STXBP1-RD as a leading test case for precision medicine in DEEs.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.